RESEARCH USE AND EDUCATIONAL DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
PE-22-28, also called mini-spadin, is an experimental peptide investigated in research on the TREK-1 potassium channel. Studies in cells and rodents have examined channel activity, behavioral responses and markers associated with neuronal growth. These findings support further investigation of the pathway, but they do not establish a treatment for depression or stroke in people. This overview distinguishes PE-22-28 from parent spadin and modified analogs, while explaining what the original experiments actually measured. [1–3]
THE EARLIER SPADIN RESEARCH
Mazella and colleagues reported in 2010 that spadin, a peptide derived from the sortilin propeptide, inhibited TREK-1 in experimental preparations. TREK-1 is a potassium channel involved in regulating electrical activity across cell membranes. The researchers also observed changes in rodent behavioral tests and markers associated with hippocampal neurogenesis, the formation of new neurons. [1]
That study helped motivate later work on shorter peptides. It did not test the clinical effectiveness of PE-22-28, and its findings should not be presented as a human trial of mini-spadin. A related molecule provides scientific background; it does not automatically supply evidence for every derivative.
WHAT THE PE-22-28 STUDY FOUND
Djillani and colleagues described a seven-amino-acid fragment, PE-22-28, in 2017. In engineered cells, it inhibited TREK-1 at substantially lower concentrations than parent spadin under the study's assay conditions. The investigators also tested several chemically modified versions. [2]
Mouse experiments reported reduced immobility in the forced-swim test and altered feeding latency in a novelty-based test. Other measurements included increased hippocampal cell-labeling associated with neurogenesis and higher levels of PSD-95, a synapse-associated protein, in cultured mouse neurons. [2]
These endpoints are useful for investigating mechanisms, but none directly measures recovery from human depression. Stronger inhibition in one laboratory assay also does not mean a compound provides proportionally greater clinical benefit. The paper's prolonged behavioral effects involved particular modified analogs; they should not be converted into a universal human half-life for unmodified PE-22-28.
WHY THE STROKE MODEL ADDS CONTEXT
Pietri and colleagues investigated mini-spadin in a mouse model of focal brain ischemia in 2019. Their electrical recordings showed a concentration-dependent response: TREK-1 activity increased under some conditions and decreased under others. This complicates a simple description of mini-spadin as always blocking the channel. [3]
In the animal experiment, the researchers reported improvements in selected motor, cognitive and behavioral measures, alongside changes in neuronal and synaptic markers. The experimental design combined different phases of intervention after induced injury. It does not establish a stroke-recovery protocol or a psychiatric treatment for people. [3]
The distinction between experimental behavior and a clinical diagnosis matters here. Rodent tests model selected processes; they cannot reproduce the full experience, symptoms or functional consequences of a human disorder.
HOW TO READ THE EVIDENCE
The publications reviewed here are preclinical studies, with overlapping investigators. They should not be portrayed as multiple independent clinical confirmations. Important unanswered questions include reproducibility, the properties of the exact compound tested and whether findings translate beyond the experimental models.
A research product's name alone does not verify that it matches the material used in a publication. Peptide sequence, chemical modifications and analytical characterization matter. The current evidence discussed here supports laboratory investigation of TREK-1 and neuronal signaling, not personal use or claims of established human safety.
REFERENCES
1. Mazella J, Pétrault O, Lucas G, et al. Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biology. 2010;8:e1000355.
https://doi.org/10.1371/journal.pbio.1000355
2. Djillani A, Pietri M, Moreno S, Heurteaux C, Mazella J, Borsotto M. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Frontiers in Pharmacology. 2017;8:643.
https://doi.org/10.3389/fphar.2017.00643
3. Pietri M, Djillani A, Mazella J, Borsotto M, Heurteaux C. First evidence of protective effects on stroke recovery and post-stroke depression induced by sortilin-derived peptides. Neuropharmacology. 2019;158:107715.
https://doi.org/10.1016/j.neuropharm.2019.107715